Executive summary
The U.S. Court of Appeals for the Fifth Circuit has vacated the FDA’s marketing denial order (MDO) against NicQuid LLC, finding that the agency’s application of a comparative-efficacy standard for flavored electronic nicotine delivery systems (ENDS) constituted a substantive rule requiring formal rulemaking under the APA. The court did not dispute the FDA’s authority to evaluate public health trade-offs, but ruled that such standards cannot be established through informal adjudication. The case is remanded for further proceedings.
Regulatory signal: The FDA cannot impose binding, broad policy standards via individual MDOs without prior notice-and-comment rulemaking.
What happened
The FDA issued an MDO in 2024 denying NicQuid LLC’s application for a flavored ENDS product, citing the agency’s internal comparative-efficacy standard. This standard required applicants to demonstrate that their product offered a net public health benefit compared to existing alternatives, particularly combustible cigarettes. The Fifth Circuit, in a unanimous decision, held that this standard had evolved into a substantive regulatory rule with broad application across the market, not merely a case-specific determination.
Under the APA, any rule that establishes binding legal standards must undergo notice-and-comment rulemaking. The court found that the FDA had not done so, thereby violating procedural due process. The decision specifically emphasized that while the FDA retains authority to assess public health impacts, it cannot use informal adjudications to create or enforce sweeping policy criteria.
The court remanded the case back to the FDA for reconsideration under proper procedural safeguards. It did not rule on the merits of NicQuid’s product or its public health impact, but focused solely on the legality of the agency’s procedural approach.
Why it matters
This ruling represents a pivotal procedural check on FDA authority in the ENDS regulatory space. The agency has relied heavily on comparative-efficacy assessments in recent years to deny applications—particularly for flavored products—on the grounds that they may not offer sufficient public health benefit over combustible cigarettes. However, this decision establishes that such standards, once applied broadly, must be formally adopted through rulemaking.
It also raises questions about the validity of prior MDOs that relied on similar reasoning. If the FDA cannot retroactively apply a standard without notice-and-comment, many existing denials may face legal challenge. The decision reinforces the principle that agencies cannot circumvent statutory procedural requirements by labeling policy decisions as case-specific adjudications.
Market impact
For the vaping industry, this decision opens a window of opportunity for brands with pending or previously denied applications. Companies that were denied on the basis of a comparative-efficacy standard may now refile or challenge prior denials on procedural grounds. The ruling could lead to a wave of appeals or new applications, particularly from smaller manufacturers who previously lacked the resources to contest MDOs.
Flavored vape products, which have been a primary target of FDA enforcement, may see renewed regulatory momentum. The decision does not mandate approval of any product, but it does invalidate a key tool the FDA has used to block market entry. This could accelerate product innovation and diversification, especially in the premium and youth-appeal segments.
Market signal: Procedural vulnerabilities in FDA’s MDO process may trigger a surge in appeals and new applications for flavored ENDS.
Regulatory impact
The ruling sets a precedent that could reshape how the FDA develops and enforces policy in the ENDS space. Going forward, any attempt to establish a broad public health standard—such as comparative efficacy, harm reduction thresholds, or youth appeal metrics—must go through formal rulemaking. This will slow down the regulatory process but increase legal defensibility.
It also signals judicial skepticism toward the FDA’s use of informal adjudication to create binding policy. The agency may now be forced to engage in public consultations, draft proposed rules, and accept public comments before implementing new standards. This could lead to greater transparency but also longer timelines for regulatory decisions.
Who is affected
- ENDS manufacturers: Particularly small and mid-sized brands with pending or denied applications.
- Regulatory counsel: Legal teams advising on FDA submissions must now assess procedural compliance for all policy-based denials.
- Public health advocates: Groups supporting or opposing flavored vape access may need to engage in rulemaking processes rather than relying on MDO outcomes.
- State and local regulators: May face increased pressure to fill regulatory gaps left by federal procedural delays.
- Investors in vape startups: May reassess risk profiles as the path to market becomes more uncertain but potentially more accessible.
Dawsen Take
The Fifth Circuit’s decision is not a victory for flavored vapes per se, nor a rejection of the FDA’s public health mission. Rather, it is a procedural correction that reinforces the rule of law in administrative governance. The FDA remains empowered to evaluate public health trade-offs, but it cannot do so through backdoor rulemaking. This case marks a turning point in the balance between regulatory authority and procedural accountability in the U.S. vaping market.
What to watch
Monitor the FDA’s response to the remand. Will the agency initiate formal rulemaking to codify the comparative-efficacy standard? If so, expect a public comment period and potential industry pushback. Also watch for similar challenges to other MDOs based on uncodified standards. The outcome will determine whether the agency can maintain its current enforcement posture or must restructure its approach entirely.
Additionally, track whether other circuits follow the Fifth Circuit’s reasoning. A split in appellate rulings could lead to Supreme Court review, which would settle the scope of agency rulemaking authority in tobacco product regulation.
For more daily vaping news, check out dawsenai.com.
Original source: 2FIRSTS | U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
Written by
Comments
